DiaMedica Therapeutics (NASDAQ:DMAC) Releases Quarterly Earnings Results, Hits Expectations

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21), FiscalAI reports.

DiaMedica Therapeutics Price Performance

DiaMedica Therapeutics stock traded down $0.30 during midday trading on Friday, reaching $9.03. The stock had a trading volume of 133,080 shares, compared to its average volume of 201,021. The firm’s fifty day simple moving average is $8.16 and its two-hundred day simple moving average is $7.20. DiaMedica Therapeutics has a twelve month low of $5.24 and a twelve month high of $11.00. The firm has a market cap of $486.72 million, a price-to-earnings ratio of -12.53 and a beta of 0.95.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on DMAC shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of DiaMedica Therapeutics in a report on Tuesday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen raised DiaMedica Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, DiaMedica Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $12.00.

View Our Latest Stock Analysis on DMAC

DiaMedica Therapeutics Company Profile

(Get Free Report)

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.

Featured Stories

Earnings History for DiaMedica Therapeutics (NASDAQ:DMAC)

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.